Professional Documents
Culture Documents
SGE; 0410-1, 48
SGE; 0410-1, 48
Which one?
SGE; 0410-1, 48
SGE; 0410-1, 48
SGE; 0410-1, 48
SGE; 0410-1, 48
Which one?
SGE; 0410-1, 48
SGE / jd 02_06
Clopidogrel only after angiogram when decision for stent implantation is made Primary PCI IIb/IIIa investigator discretion (clopidogrel if stent)
Pre-treatment with Full Dose TNK followed by Primary PCI IIb/IIIa bail out only* (clopidogrel if stent)
Primary Endpoint * : Composite of Death or Cardiogenic Shock or Congestive Heart Failure within 90 Days
* Used in only 9.6%
Acute MI
Platelet Activation by Fibrinolytics
Normalized Maximal Aggregation Rate
1.5
t-PA SK
1.0
Time (min)
Rabbit model, .05mM ADP as agonist
Rudd and Loscalzo, CircRes 90 SGE; 0802-3, 22
Placebo Abciximab
Transfer To Cath Lab ASA, unfractionated heparin 40U/kg (max 3000u) or enoxaparin (0.5 mg/kg IV + 0.3 mg/kg SC) substudy only (0 5 03
Abciximab
Placebo
Primary PCI with Abciximab Infusion (12 h)
Placebo
Primary endpoint at 90 days: All-cause mortality, resuscitated VF occurring > 48H, cardiogenic shock, or readmission/ED visit for CHF
p=.093
9.9% 10.0% 6.5%
Primary PCI with In Lab Abciximab Abciximab Facililated PCI Abciximab/Reteplase Facilitated PCI
9 8 7 6 5 4 3 2 1 0 0 3 6
7.7%
4.8%
5.9% 5 9%
3-yr HR [95%CI]= 0.75 [0.58, 0.97] P=0.03
3.4%
1-yr HR [95%CI]= 0.71 [0.51, 0.98] 0 71 [0 51 0 98] P=0.04
9 12 15 18 21 24 27
30
33
36
Months
1800 1802 1689 1670 1660 1643 1633 1593 1611 1568 1574 1525 1098 1043
Impact of Pre-randomization Heparin in Prethe HORIZONS-AMI Trial HORIZONS30 Day MACE 10 8 6 4.6 4 2 0 5.6 7.2 5.2 52
30 Day Major Bleeding 10
Impact of Pre-randomization Heparin in Prethe HORIZONS-AMI Trial HORIZONS30 Day MACE 10 8 6 4.6 4 2 0 5.6 7.2 5.2 52 30 Day Major Bleeding 10 8.5 8 6 4.8 4 2 0 5.2 52 Bivalirudin Heparin + GP IIb/IIa 7.5
STEMI
Importance of Early Heparin Administrative/Horizons
Pre Randomization Heparin 3.0 2.5 Acute Stent % 1.5 Thrombosis 1.0 10 0.5 0.0 0.1 01 Bivalirudin Randomized Heparin + G I epa GP
SGE; 0310-3, 72
P = 0.006
2.6 26
Yes Y No
2.0
P = 0.02
0.9 09
0.8
STEMI patients N=3,534 N 3 534 Within 14 days for ongoing or recurrent ischemia
Clopidogrel N=1,235
Prasugrel N=1,203
Clopidogrel N=530
Prasugrel N=564
SGE; 0411-1, 8
CV Death / MI / Stroke
12.4% 10.0%
Percen (%) nt
10
180 270 360 Days From Randomization Montalescot et al Lancet 2008.Adapted with permission
from Antman EM.
30 60 90
450
SGE; 0410-8, 31
2.4%
2.0
1.0
0.0
50
100
150
300
ASA, Prasugrel*, heparin, BB, statins *May give with PCI (clopidogrel needs loading) g)
SGE; 0410-1, 48
SGE; 0410-1, 48
CARESS-INCARESS-IN-AMI: Design N g
Designed to address optimum treatment in pts for whom primary PCI not readily a a ab e available Comparison, after half dose reteplase+abciximab, between routine etep ase abc ab, bet ee out e immediate referral for cath/PCI and selective rescue PCI approach in pts who do not qualify for primary angioplasty High risk patients only (Killip class > 2, EF <35%, ST elevation cumulative > 15 mm)
10.7%
4.4%
HR=0.40 (0.21-0.76)
SGE; 0410-8, 64
Transfer AMI
Cath/PCI After Lysis: Routine or Rescue?
1,059 pts STEMI <12 hrs >48 and any of: SBP <100, 24 - <48 HR>100, Killip 2-3 or 212 - <24 RVMl rxd with Tenecteplase 11 - <12 10 - <11 R routine or 9 - <10 rescue b based angio/PCI d i /PCI 8 - <9 Concomitant rx: 7 - <8 ASA +/- Clopidogrel; +/6 - <7 5 - <6 UF or LMWH 4 - <5 1 endpoint: death, re-MI, re3 - <4 rec ischemia, CHF, 2 - <3 CGS @30 days 1 - <2
0 - <1
1.0
0.8 0.6 06 0.4
Routine early PCI, Standard Treatment, (N=529) (N=463) Routine early PCI PCI, Standard Treatment, Treatment (N=463) (N=529)
10
15
20
25
30
Standard Treatment
No. of Patients
50
10
15
20
25
30
522 537
432 478
SGE; 0609-6, 29
GRACIA I 500 Patients 0.5 12 0 5-12 hrs of sx ST elevation in 2 leads Excluded: shock or pressor dependency Randomized to either routine cath PCI within 24 hrs or Ischemia only driven cath (20% crossover) 1 end pt: death, MI or ischemia reg revasc at 12 months Fernandez-Aviles Lancet 04
30
Conservative
20
intervention
10 0
2 230 225
4 228 217
6 226 211
8 223 208
10 222 202
12 221 195
20
Conservative
10
intervention
10
12
236 235
235 230
232 226
229 225
228 221
227 217
SGE; 0411-11, 1
10 5 0
10%
Death
Bohmer E. JACC 55:102, 2010 n=266 patients > 90 min from FMC->PCI, rxd with FMCtenecteplase (not selected for high risk) Invasive- PCI (89%) 163 min, Cons (71%) Invasive3 days after TNK
SGE; 0410-1, 13
SGE; 0410-1, 48
SGE; 1109-9, 32
SGE; 1109-9, 32